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Abstract: Hemophilia is a rare genetic bleeding disorder that, if not adequately controlled, is 
associated with life-threatening bleeding events and serious and costly complications, primarily 
from joint damage. The advent of effective clotting factor replacement therapy for patients 
with hemophilia is considered one of the foremost medical advances of the 20th century. The 
last 3 decades of experience in hemophilia care have witnessed the effectiveness of the care 
of patients with hemophilia within specialized comprehensive care centers, advances in factor 
replacement therapies, the beneﬁ  ts of prophylaxis over on-demand replacement therapy, and 
the role of aggressive management of joint disease to prevent dysfunction. Ongoing challenges, 
including the management of inhibitors to factor therapies and the consequences of thousands 
of patients with hemophilia becoming infected with human immunodeﬁ  ciency virus and 
hepatitis C virus in the 1980s from contaminated plasma-derived factor concentrates, have 
highlighted the need for vigilance with respect to clotting factor product safety, access to care, 
and a full complement of choice of factor replacement therapies. Advate® (antihemophilic 
factor [recombinant] plasma/albumin-free method [rAHF-PFM]) is the ﬁ  rst recombinant factor 
VIII therapy manufactured without human or animal protein additives to eliminate the risk of 
pathogen transmission that could be carried by these additives. Preclinical studies established 
bioequivalence with recombinant antihemophilic factor (Recombinate®), a product with 16 years 
of clinical experience. Currently licensed in 44 countries worldwide, rAHF-PFM has over 7 years 
of clinical research within 5 global studies supporting its safety and efﬁ  cacy in the treatment 
of patients with hemophilia A.
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Primer on hemophilia therapy
Epidemiology
Hemophilia A or hemophilia B are rare genetically inherited bleeding disorders caused by a 
deﬁ  ciency of blood clotting factors VIII (FVIII) or IX, respectively. Hemophilias A and B 
have an incidence of 1 in 5000 and 1 in 25,000 male births, respectively. Their combined 
prevalence is estimated to be 13 cases per 100,000 or approximately 17,000 cases in 
the United States.1 Hemophilia A accounts for the great majority (~85%) of cases of 
hemophilia. Disease severity is closely correlated with the level of factor deﬁ  ciency and 
can be categorized as mild, moderate, and severe (Table 1); of patients with hemophilia, 
approximately 9000 have severe disease.
Clinical impact
The clinical manifestations of hemophilia are bleeding and bruising, with the extent 
depending on the severity of the disease. Common sites of bleeding are the joints, soft Biologics: Targets & Therapy 2009:3 118
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tissues and muscles, and to a lesser extent, the mouth, gums, 
and nose, and the central nervous system. Bleeding in the 
joints (hemarthrosis) is the most common problem in people 
with severe hemophilia. Individuals with severe hemophilia 
may experience frequent recurrent bleeding into their joints 
or muscles, usually one to two times per week. Those with 
moderate hemophilia may experience a bleeding episode 
only once a month, as these patients normally experience a 
bleeding episode only after injury. In contrast, people with 
mild hemophilia may experience a bleeding episode less 
frequently, and usually as a result of surgery or major injury. 
Uncontrolled or inadequately treated recurrent bleeding into 
a patient’s joints results in severe morbidity and irreversible 
physical disability (hemophilic arthropathy).2 This can result 
in hospitalization, additional therapy, and, in rare cases, open 
or arthroscopic synovectomy or joint replacement surger-
ies. In addition to a risk for mortality and hemarthrosis and 
arthritis, the risk for serious and life-threatening infections 
can also complicate the management of hemophilia.
Impact on quality of life
Another complication of hemophilia is the impact on health-
related quality of life (HRQOL). In a study of HRQOL, data 
from patients with hemophilia were compared with normative 
data. Patients with hemophilia had signiﬁ  cantly lower scores 
on HRQOL measures based on the Short Form 36 Health 
Survey (eg, physical functioning, bodily pain, general 
health, and social functioning) as compared with normative 
data.3,4 Speciﬁ  cally, patients with severe hemophilia had 
lower scores on physical measures compared with nor-
mative subjects (physical component scale [PCS] = 31.9 
vs 52.0, respectively).3 In another study evaluating the 
academic achievement in children with hemophilia, patients 
with  11 bleeding episodes per year achieved higher math 
(103.6 vs 99.6; p = 0.030) and total achievement scores (as 
determined by the Wechsler Individual Achievement Test, 
104.4 vs 100.6; p = 0.026) than patients with  12 bleeding 
episodes per year. The number of bleeding episodes is also 
correlated positively with school absenteeism, which may 
have contributed to a decrease in achievement.5
Cost impact
Treatment for hemophilia, which requires therapy with factor 
concentrates, can be costly, especially with the advent of 
new technologies. The annual cost for factor therapy for 
the treatment of bleeding in severe hemophilia can range 
from US$60,000 to greater than US$150,000 per patient.6 
However, treatment for the preventable complications of 
hemophilia can increase health care costs substantially 
beyond the ﬁ  xed cost of replacement therapy.7 The presence 
of mild or moderate arthropathy can potentially increase the 
cost by 146% and 267%, respectively (p   0.01 compared 
with no arthropathy).6
Treatment
The primary goal of hemophilia practitioners is to enable 
patients to live as actively and productively as possible, with 
minimal complications either from their disease or from any 
adverse effects associated with therapy. The cornerstone 
of such therapy is FVIII replacement therapy. The selec-
tion of an optimal factor replacement therapy is complex 
and requires that diverse elements be considered for each 
individual patient. These include family and individual his-
tory, efﬁ  cacy, inhibitor risk, supply, reimbursement options, 
patient cost, infusion characteristics that contribute to com-
pliance, and each therapy’s vulnerability to blood-borne 
infectious agents.8
Prophylaxis and on-demand treatment regimens
Treatment for patients with hemophilia requires the infusion 
of clotting factor derived either from fractionation of human 
plasma or through recombinant deoxyribonucleic acid (DNA) 
technology. Plasma-derived FVIII concentrates (pdFVIII) 
are derived from large pools of human donor plasma while 
recombinant FVIII (rFVIII) concentrates are produced from 
mammalian cell lines (eg, Chinese hamster ovary, CHO, 
cells) genetically altered to express human FVIII.9
Replacement therapy with factor concentrates can be 
administered at home or in a physician’s ofﬁ  ce and can be 
used prophylactically to prevent bleeding or on-demand 
to stop bleeding when it occurs. The number of infusions 
required for each bleed and, over time, the number of units 
of clotting factor needed per infusion, depends on the sever-
ity and location of the bleed, the severity of overall disease, 
and the patient’s weight. Prophylactic therapy is most often 
Table I Hemophilia A clinical classiﬁ  cation
Classiﬁ  cation
Severe Moderate Mild
FVIII activity 
(% of normal)
 1% 1%–5%  5%– 40%
Pattern of bleeding 
episodes
24–48 per year 4–6 per year Uncommon
Cause of bleeding 
episodes
Spontaneous Minor trauma Major trauma
Surgery
Adapted from White et al.51Biologics: Targets & Therapy 2009:3 119
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used for people with severe hemophilia, and can be given 
on a long-term basis or on a shorter-term basis, lasting a few 
months. Prophylaxis commonly involves single or multiple 
weekly infusions when there is no acute bleeding, in order 
to prevent bleeds and cumulative musculoskeletal damage. 
On-demand therapy is less intensive and is commonly used 
for people with mild or moderate hemophilia, or for those 
patients with severe disease who are unable to sustain pro-
phylactic therapy.
Clotting factor therapies exhibit notable interindividual 
pharmacokinetic variability.10 Therefore, it is important 
that the patient’s clinical status, the severity of the disease, 
and the location and extent of bleeding be reviewed when 
tailoring FVIII dosing schedules to an individual patient. 
For on-demand therapy, optimal replacement therapy for 
acute bleeding should raise plasma levels to 50% to 100% 
of normal for life- or limb-threatening bleeds, and to 30% 
to 50% for lesser bleeds.
Prophylaxis is considered the optimal therapy for children 
with severe hemophilia.11–13 It has proven efﬁ  cacious in pre-
venting bleeds and joint disease.2 This also correlates with 
a reduction in hospital admissions, emergency department 
and clinic visits,14 and improved academic performance and 
accomplishments.5,15 Additionally, prophylactic regimens 
may be associated with reduced risk for inhibitor develop-
ment to factor therapy.16 Prophylactic therapy also has been 
shown to improve HRQOL compared with on-demand 
therapy.3,4,17
Historical safety concerns with factor VIII therapy
In 1982, the CDC reported a ﬁ  nding that would ultimately 
change the course of modern medicine. A highly unusual 
immunosuppressive disorder was detected in 3 patients with 
hemophilia.18 Within 2 years of this report, it is estimated 
that 63% of the 15,500 patients living with hemophilia in the 
United States contracted HIV from plasma-derived clotting 
concentrates.19
Despite epidemiologic evidence at the time that strongly 
suggested that blood and blood therapies could transmit HIV, 
opportunities to implement control strategies were seen as 
“ineffective, too costly, or too risky” by the blood banks, the 
US Food and Drug Administration, and the plasma fraction-
ation industry.20 As detailed in a report issued in 1995 by the 
Institute of Medicine (IOM), new infections with HIV and 
fatalities in patients with hemophilia continued to rise while 
debates among these organizations delayed comprehensive 
action. Many physicians and health systems continued to 
urge patients to remain on plasma-derived clotting factor con-
centrates.21 Sadly, in the absence of effective antiretroviral 
therapy throughout the early years of the AIDS epidemic, 
most patients with hemophilia infected with HIV died.22 In 
1993, the IOM held a series of hearings to provide an objec-
tive and impartial review of the decision-making processes 
and policies that surrounded the contamination of the blood 
supply with HIV. As a consequence of the hearings, in 1995 
the IOM published HIV and the Blood Supply: An Analysis 
of Crisis Decisionmaking, which offered clear guidelines to 
preserve and restore the safety of our nation’s blood supply 
and avoid future public health crises.20
The signiﬁ  cant advances in blood donor screening and 
blood therapy testing and the adoption of heat-treated factor 
concentrates reduced the risk for exposure to HIV through 
blood by the early 1990s. The incidence of HIV transmission 
in patients with hemophilia fell substantially: the number of 
HIV-related deaths in the hemophilia population decreased 
75% between 1995 and 1998.20 In hemophilia birth cohorts 
born from 1985 onward, no HIV infection from clotting 
factor therapies occurred in patients.23 The introduction of 
rFVIII has also had a marked impact; in fact, as a result 
of recombinant therapy use, no seroconversions to HIV, 
hepatitis B virus (HBV), or HCV have been reported.24 In 
the United Kingdom, the estimated frequency of infectious 
HIV donations entering the blood supply from 1996 to 2003 
was 0.14 per million.25
Although the fear of HIV transmission has largely sub-
sided, the very serious threat posed by new blood-borne 
pathogens has been recognized. The threat of newly emerging 
pathogens and concerns over their potential impact on the 
hemophilia community still remain today. Thus, a key com-
ponent of hemophilia management is recognition that patients 
with hemophilia remain vulnerable to potential contamina-
tion of the blood supply and clotting factor therapies.
To ensure the safety of the blood supply, 10 tests are 
now routinely performed for 8 known pathogens on each 
unit of donated blood in the United States. However, many 
potentially blood-transmissible pathogens are not currently 
included in testing protocols. These infectious agents fall 
into 3 broad categories: (1) known viruses perceived as a 
low health risk and rarely transmitted, such as hepatitis A; 
(2) newly identiﬁ  ed viruses such as hepatitis G; (3) emerg-
ing/spreading viruses and pathogens for which screening 
procedures have not yet been developed, or whose threats to 
the blood supply have not yet been assessed or documented. 
This third category currently includes pathogens with sub-
stantial potential for causing illness and even death, such 
as West Nile virus26 and prions. Prions, the etiologic agent Biologics: Targets & Therapy 2009:3 120
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associated with variant Creutzfeldt-Jakob disease (vCJD), has 
been deﬁ  ned as one of the signiﬁ  cant potential new threats 
to the blood supply.27 First identiﬁ  ed in 1996, the impact of 
vCJD on the clinical practice of hemophilia has been pro-
found, especially given the legacy of HIV and HCV in the 
hemophilia community.28 In the United Kingdom, despite 
measures to inform all patients about the possible risk for 
transfusion-transmitted vCJD, many patients’ conﬁ  dence in 
their therapies has been eroded and some patients fear that 
their medical and surgical care will be interrupted because of 
stigmatization, as in the early years of the HIV crisis. These 
concerns are underscored by a recent study that examined 
48 individuals who received a labile blood component from 
15 donors who later developed vCJD (55 labile components 
originating from these 15 donors were issued to hospitals, 
48 of these were transfused to recipients, with the remaining 
7 components sent to hospitals that were unable to trace their 
fate).29 One of the recipients received a blood transfusion 
from a donor who died of pathologically conﬁ  rmed vCJD 
3.5 years after donating blood. The recipient died after 
developing symptoms of dementia, 6.5 years following the 
transfusion. Additional cases have been described establish-
ing that the infectious agent can be transmitted by blood 
components. However, to date there is no evidence that the 
infectious agent has been transmitted by fractionated plasma 
components, eg, pdFVIII.30 Until a sensitive blood screening 
test is made available, it is difﬁ  cult to quantify the absolute 
risk for additional vCJD transfusion-related cases. For this 
reason, continued vigilance is important to the response to 
prion-mediated disease.
The awareness among practitioners that vulnerability 
to emerging pathogens varies by blood clotting therapy 
is another important component of hemophilia care. 
Some rFVIII therapies still incorporate trace amounts of 
human- or animal-derived albumin. Inactivation tech-
niques are used as part of the processing procedures for 
all factor therapies that incorporate plasma or plasma 
additives. Lipid-enveloped pathogens such as HIV, HBV, 
and HCV are readily eliminated. However, inactivation 
measures are only partly or not at all effective in removing 
or inactivating nonlipid-enveloped viruses, such as human 
parvovirus B19 (PVB19) and prions.31–33 PVB19 has been 
isolated from plasma-derived coagulation factor concentrates 
and ﬁ  rst-generation rFVIII therapies.34,35 However, data 
suggest that risk for PVB19 transmission by recombinant 
antihemophilic factor is low.36
To address the ongoing concern over potential contamina-
tion of blood and blood therapies, national medical councils 
and physician advisory bodies in the United Kingdom, the 
United States, Australia, and Canada have independently 
addressed the need for ongoing vigilance regarding infectious 
agents in rFVIII replacement therapies. Recently, the UK 
Haemophilia Centre Doctors’ Organisation, the US National 
Hemophilia Foundation, and the Association of Hemophilia 
Clinic Directors of Canada have all issued speciﬁ  c guidelines 
advocating the elimination of albumin from every stage 
in rFVIII processing.24,37,38 The proactive stances taken by 
these groups, including national health systems, highlight 
the public support for providing therapies with the least 
vulnerability to pathogens. According to a report in 2004 
by the CDC, the majority of patients with bleeding disorders 
now use recombinant therapy.39 Of nearly 14,000 people 
registered in the CDC Universal Data Collection surveillance 
program, 62.7% of patients with hemophilia A and 56.1% 
of patients with hemophilia B used a recombinant therapy 
in the preceding year.
Development of rAHF-PFM
Due to the continuing concern within the hemophilia 
community about potential risks surrounding the use of 
plasma-derivatives or bovine additives in the cell culture, 
processing, and formulation of rFVIII, new rFVIII formu-
lations removed human albumin as a stabilizer from the 
ﬁ  nal formulation. However, these “second generation” 
rFVIII concentrates still may contain residual amounts 
of protein additives from the cell culture or puriﬁ  cation 
processes. Therefore a “third generation” processing and 
formulation ultimately resulted in the complete removal 
of all human- and animal-derived additives from the cell 
culture process, puriﬁ  cation and ﬁ  nal formulation and 
designated recombinant anti-hemophilic factor plasma/
albumin-free method, or rAHF-PFM. The rAHF-PFM 
process is highly similar to that for the ﬁ  rst generation 
rFVIII, Recombinate® (rAHF), and incorporates: (1) the 
adaptation of the CHO cells to new culture conditions 
free of human- and animal-derived additives; (2) the 
optimization of the fermentation technology aiming at 
increased homogeneity and viability of the cells; (3) 
creation of a new master cell bank; (4) adaptation of the 
monoclonal antibody production used in the immune 
afﬁ  nity puriﬁ  cation step to conditions free of human- and 
animal-derived additives; (5) a dedicated solvent/detergent 
(S/D) viral inactivation procedure; and (6) a new non-
sucrose containing ﬁ  nal formulation principally comprised 
of mannitol, trehalose, and buffered salts was developed in 
order to replace the use of albumin as a stabilizer (Table 2). Biologics: Targets & Therapy 2009:3 121
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Extensive preclinical testing with rAHF-PFM revealed a 
high degree of biochemical, biophysical, and biological 
similarity with rAHF.40
Since the development of the ﬁ  rst rFVIII, a wealth of 
clinical information has been developed to assess the hemo-
static response of standard and modiﬁ  ed recombinant clotting 
factor concentrates for patients in the United States with severe 
or moderately severe hemophilia A. These therapies include 
the “ﬁ  rst-generation” therapy, Recombinate® (antihemophilic 
factor [recombinant]) (rAHF); the “second-generation” 
therapies, Kogenate® FS (antihemophilic factor [recombinant]) 
(KFS), and ReFacto® (antihemophilic factor [recombinant]) 
(RF) (a B-domain–deleted rFVIII); and “third-generation” 
recombinant therapy, Advate® (antihemophilic factor 
[recombinant], plasma/albumin-free method) (rAHF-PFM) 
(Table 3). Recently, the manufacturing process for RF has 
been modiﬁ  ed to add another third-generation recombinant 
therapy, Xyntha™ [antihemophilic factor (recombinant) 
plasma/albumin-free]. To date, there have been no published 
head-to-head trials of these commonly prescribed therapies 
for hemophilia.
Efﬁ  cacy of rAHF-PFM
To assess the clinical response to therapy, 2 populations of 
patients with hemophilia are normally studied: previously 
untreated patients (PUPs) and previously treated patients 
(PTPs). Factor replacement regimens are evaluated in 
patients receiving either therapy for prophylaxis of bleeding 
episodes (including surgery) or on-demand therapy for acute 
bleeding episodes. Efﬁ  cacy, as determined by achievement 
of hemostasis, is evaluated in some studies using a 4-point 
rating scale. “Excellent” is deﬁ  ned as arrest of bleeding with 
abrupt pain relief within 8 hours; “Good” is deﬁ  ned as pain 
relief or reduction of bleeding that was delayed or required 
more than 1 infusion; “Fair” is deﬁ  ned as a probable or slight 
Table 2 Production and processing of rAHF-PFM
Fermentation technology Continuous chemostat perfusion
Cell culture medium Protein-free medium
Puriﬁ  cation • Immunoafﬁ  nity chromatography 
     Monoclonal antibodies expressed 
in plasma/albumin-free conditions 
•  Cation exchange chromatography
• Anion exchange chromatography
Viral inactivation Solvent/detergent treatment
Stabilizer Trehalose
Bulking agent Mannitol
beneﬁ  cial response; “None” is no response. In many trials, 
patients are monitored for years.
Pharmacokinetics, efﬁ  cacy, safety 
and immunogenicity in PTPs
The Global Clinical Trial Program for rAHF-PFM has 
included 5 completed clinical trials.40 In the Pivotal study41 
of rAHF-PFM in PTP’s   10 years of age, the primary 
aims were to demonstrate the pharmacokinetic properties 
of rAHF-PFM and to demonstrate safety and efficacy 
in bleed control and prevention. The study comprised 
1) a double-blind, crossover, pharmacokinetic comparison 
of rAHF and rAHF-PFM, 2) prophylaxis 3 to 4 times per 
week with 25 to 50 IU/kg over at least 75 exposure days 
and 3) treatment of episodic bleeding events. The long-term 
safety and efﬁ  cacy of rAHF-PFM was evaluated in 81 sub-
jects from the pivotal study who enrolled in an open-label, 
two-part continuation study13 consisting of 1) a comparison 
of pharmacokinetics before and after  75 exposure days to 
rAHF-PFM and 2) safety, immunogenicity and hemostatic 
efﬁ  cacy of 3 different therapeutic regimens with rAHF-PFM: 
standard prophylaxis of 25 to 40 IU/kg, 3 to 4 times per 
week; modiﬁ  ed prophylaxis as per the discretion of the 
investigator; and on-demand therapy. The pharmacokinetics, 
efﬁ  cacy, safety and immunogenicity of rAHF-PFM in PTP’s 
less than 6 years of age were evaluated in the pediatric PTP 
study42 wherein subjects were treated according to standard 
prophylaxis, modiﬁ  ed prophylaxis or on-demand therapy. 
The safety and efﬁ  cacy of rAHF-PFM in PTPs undergoing 
surgical, dental or other invasive procedures was assessed in 
a multicenter, prospective, open-label, uncontrolled surgery 
study.43 Finally a Japanese Registry study13 assessed the 
pharmacokinetics, efﬁ  cacy, safety and immunogenicity of 
rAHF-PFM in 15 Japanese PTPs, utilized a study design 
similar to the Pivotal study, and yielded similar results.
Pharmacokinetic assessment
Bioequivalence was demonstrated between rAHF-PFM and 
rAHF based on area under the plasma concentration vs time 
curve and adjusted recovery following a 50 ± 5 IU/kg infu-
sion in a randomized, crossover protocol. Mean (±SD) plasma 
half-life was 11.98 ± 4.28 hours. There was substantially less 
variance in the plasma half-life observed within subjects than 
among subjects. Pharmacokinetic parameters were similar 
at the initiation of the trial product and after  75 exposure 
days as assessed in the continuation study.
Within the pediatric study, half-life, adjusted recovery 
and area under the curve parameters were all lower compared Biologics: Targets & Therapy 2009:3 122
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to observations within the older subjects in the pivotal trial. 
Proposed variables affecting the pharmacokinetic parameters 
include methodologic (pediatric subjects had a delayed ﬁ  rst 
time point of 1 h post-infusion which is beyond when the 
peak level was observed in many of the older patients in the 
Pivotal trial) and physiologic differences (eg, differences in 
plasma volume to weight ratios, changes in recovery related 
to body mass index).
Treatment of bleeding episodes
During the pivotal study, 510 new bleeding episodes in 
83 PTP’s were treated with rAHF-PFM at a mean dose per 
infusion of 38.1 IU/kg. Bleeding events were related to trauma 
(45%), spontaneous (32%) or undetermined (24%). The 
majority of the bleeds were joints (52%) or muscles (33%). 
Overall, 93% of the bleeding episodes were resolved with 
1 or 2 infusions and 81% were resolved with only 1 infusion. 
Patients rated the hemostatic efﬁ  cacy as excellent or good in 
86% of the bleeding episodes with similar results regardless 
of the etiology or the anatomic site of bleeding.
In the continuation study, 70 of the 81 subjects reported 
822 bleeding episodes, whereas 11 subjects (all of whom 
were on prophylaxis) reported no bleeding episodes. Among 
the 820 bleeding episodes that were treated, 88.5% were 
managed with one or two infusions.
In the pediatric study, 354 of the 409 reported bleeds were 
treated with rAHF-PFM. Hemostatic efﬁ  cacy was rated as 
excellent or good for 93.8% of the treated bleeding episodes 
with 90.1% requiring only 1 or 2 doses.
Breakthrough bleeding during prophylaxis
For all patients treated during the ﬁ  rst 75 exposure days in 
the pivotal study, a mean rate of 6.3 new bleeding events 
per patient per year was observed. However, the annual rate 
of bleeding varied according to patient adherence to the 
treatment regimen. Adherence was deﬁ  ned as 25 to 40 IU/kg 
per infusion for  80% of the prophylactic infusions at a 
frequency of 3 to 4 times per week for 80% of the time on 
study. Adherent patients had a mean annual rate of bleeding 
of 4.4, whereas less compliant patients had a mean of 9.9 
bleeding episodes per year. Similar to the Pivotal trial, 
subjects who were adherent to the standard prophylaxis 
regimen in the Continuation study experienced lower annual 
bleed rates (n = 30, 4.5 bleeds per year) compared with 
non-compliant subjects (n = 24, 7.9 bleeds per year).
Within the pediatric study, the median numbers of annual 
bleeds for all body sites were 4.0, 4.4 and 24.4 for subjects on 
standard prophylaxis, modiﬁ  ed prophylaxis and on-demand 
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Safety and efﬁ  cacy of rAHF-PFM in treatment of hemophilia A
therapy respectively. The median annual rate of joint bleeds 
was zero for all prophylaxis regimens compared to 14.2 for 
on-demand therapy.
Surgical prophylaxis and perioperative management 
of hemostasis
The efﬁ  cacy and safety of rAHF-PFM in haemophilia patients 
undergoing surgery was evaluated in a prospective, international, 
open-label, uncontrolled clinical trial. Patients were  5 years 
of age with baseline FVIII:C  2% and  150 prior FVIII 
exposure days. rAHF-PFM was administered perioperatively 
by bolus infusion (BI) or continuous infusion (CI). The treating 
surgeon and hematologist both evaluated the efﬁ  cacy during the 
hospitalization. Fifty-eight subjects underwent 65 surgical pro-
cedures. Twenty-ﬁ  ve procedures were considered major hemor-
rhagic risk, 35 minor and 8 were invasive dental procedures. 
The hemostatic efﬁ  cacy was rated as excellent or good for 
100% of the intraoperative and postoperative ratings for both 
BI and CI modes of administration. Data on estimated blood 
loss (EBL) were available for 58 procedures. Actual blood 
loss (ABL) was less than predicted in 27 procedures, within 
the predicted EBL range for 28 procedures and greater than 
predicted in 3 procedures. Twelve cases (9 of which were major 
orthopedic surgeries) required transfusion of red blood cells, 
fresh frozen plasma or albumin. rAHF-PFM was well tolerated 
in this surgery study with 156 adverse events (AEs) reported in 
35 subjects. Seven AEs were serious and 149 non-serious. None 
of the serious AEs were judged by the investigator to be related 
to rAHF-PFM, with 8 of the 149 non-serious AEs possibly or 
probably related. Most AEs were consistent with well-known 
complications of hemophilia, surgery or hospitalization. There 
was no difference in AEs among patients receiving BI or CI 
and no thromboembolic complications.
Within the Pediatric study, 7 patients underwent surgical 
procedures, 5 of which were evaluable per-protocol. These 
included 2 indwelling port removals, indwelling port removal 
and circumcision, excision of an ocular cyst and closed 
reduction of a nasal fracture. ABL and EBL ratios were 
unremarkable and intraoperative/postoperative hemostatic 
efﬁ  cacy was rated as excellent or good in 3 subjects where 
ratings were available.
Immunogenicity
One of the most potentially devastating complications for 
patients with hemophilia is the development of inhibitors (allo-
antibodies) to FVIII therapy. Inhibitors, measured in Bethesda 
units (BU), are classiﬁ  ed as either high titer ( 5 BU) or low 
titer ( 5 BU) and can neutralize the efﬁ  cacy of treatment. 
In addition, inhibitors may often become a barrier to future 
treatment. Therefore, the prevention of inhibitor development 
is paramount and a high value is placed on decreasing any 
risk for developing inhibitors.44
The incidence of inhibitors in PTPs is generally low. For 
example, in the pivotal rAHF trial, none of the 65 patients 
developed inhibitors after 30 months.45 In clinical studies 
with KFS, no FVIII inhibitors were reported in 71 patients 
after a mean exposure of 54 days.46 The incidence of inhibitor 
development is similar with RF; only 1 in 113 PTPs treated 
with RF developed a high titer inhibitor after 113 exposure 
days.47 After 18 months of continued therapy, however, this 
patient’s inhibitor level continued to rise and the patient was 
taken off treatment. In the Pivotal study for rAHF-PFM, 
1 of 108 PTPs tested positive for a low titer (2 BU) inhibi-
tor to FVIII following 26 exposure days. The subject was a 
55 year old male with severe hemophilia who displayed no 
symptomatic evidence of an inhibitor. Eight weeks later the 
inhibitor was undetectable. No inhibitors were detected in 
the continuation, pediatric or surgery studies.
In contrast to PTPs, inhibitors in PUPs are higher, rang-
ing from 15% to 33%. In the prospective study of PUPs 
with rAHF, 22 (31%) of 72 evaluable patients developed 
inhibitors. Of these 22 patients, 13 had low titer inhibitors 
and 9 had high titer inhibitors.48 The incidence of inhibitor 
development was comparable in 101 PUPs treated with 
RF; with 33 patients (33%) developing inhibitors.47 Of 
these, 16 patients had high titer inhibitors and 17 had low 
titer inhibitors. Finally, in an international KFS study in 
61 children that also included minimally treated patients, 
9 patients (15%; 9/60; one patient with pre-existing inhibi-
tor was excluded after his 4th infusion when the result of a 
positive inhibitor at screening was known) had developed 
inhibitors.49 However, many children in this trial remain at 
risk for developing inhibitors since they have had relatively 
few exposure days. Clinical trials with rAHF-PFM in PUPs 
are ongoing. In addition, an ongoing post-licensure safety 
surveillance study is designed to prospectively assess the 
incidence of rAHF-PFM-related non-serious adverse events 
in routine clinical practice and will provide a more accurate 
estimate of the incidence of inhibitors in a larger hemophilia 
population within real world practice.13
Conclusions
Remarkable strides in optimizing hemophilia care have 
been attained over the last several decades. In large part 
these accomplishments reﬂ  ect the advent of effective rFVIII 
therapy, specialized hemophilia treatment centers, and a Biologics: Targets & Therapy 2009:3 124
Pipe
sustained, proactive, long-term decision-making approach 
that takes into account the unique societal and medical chal-
lenges of this disease.
Current studies do not allow an evidence-based decision-
making tree to determine “best practice” with regards to 
product choice (ie, recombinant vs plasma-derived products; 
choice among several generations of recombinant products). 
Because of the HIV tragedy in the 1980s, the hemophilia 
community highly values therapies made with processes that 
minimize risk for pathogen transmission. In dealing with 
the safety of blood and blood therapies, the precautionary 
principle is generally followed. This principle posits that 
complete evidence of risk does not need to exist to take mea-
sures to protect against the risk.50 Following this principle can 
conﬂ  ict with the current practice of evidence-based decision 
making, which requires that sound evidence of an outcome 
be produced to justify action. Safety of blood therapies from 
emerging pathogens is not an outcome that can reasonably 
be measured in a clinical trial setting, which is the standard 
setting for collecting data for evidence-based decisions.
rAHF-PFM was developed in response to needs within 
the hemophilia community for a rFVIII product manufactured 
without human or animal protein additives to eliminate the 
risk of pathogen transmission that could be carried by these 
additives. Preclinical studies established bioequivalence with 
rAHF and the available clinical data support that it is compa-
rable in terms of safety and efﬁ  cacy in on-demand and pro-
phylaxis therapy. Within the Global Clinical Study program, 
208 PTPs have participated in 5 studies. No subject withdrew 
due to a rAHF-PFM-related AE, 198 had at least 10 exposure 
days or 6 months of observation and only 1 subject developed 
a non-persistent, low-titer inhibitor, and no serious adverse 
events related to rAHF-PFM have been described.
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